Welcome to QBiotics

An Australian naturally inspired life sciences company

Human Health
Animal Health
Investor Health


Pivotal canine field study results published in The Journal of Veterinary Internal Medicine reveal STELFONTA® (tigilanol tiglate) removes 75% of tumours

June, 2020

The study of 123 client-owned dogs demonstrated that in those with Mast Cell Tumours (MCTs), a single intratumoural injection of STELFONTA® removed 75% of MCTs at day 28, significantly higher compared to untreated controls (p<0.001). Further, the trial showed no recurrence in 93% of STELFONTA®-treated dogs at day 84.

QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®

April, 2020

Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for its lead compound, tigilanol tiglate, with the launch of STELFONTA® in the European markets at the Virbac Oncology Summit Webinar Event (24 April 2020).

QBiotics raises AU$17.76 million from Sophisticated Investors

February 2020

Australian life sciences company, QBiotics Group Limited (QBiotics), has completed a share placement to Sophisticated Investors with a total of AU$17,756,150 raised.  The Board authorised and approved the issue and allotment of 25,365,929 Shares at an issue price of AU$0.70 per Share to the subscribers under the Offer.

QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of STELFONTA®

January 2020

STELFONTA® (tigilanol tiglate) has been approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment available for all grades of canine non-metastatic mast cell tumours (MCT). The approval marks the first registration of QBiotics' lead compound tigilanol tiglate, which is also under review by the US Food and Drug Administration - Center for Veterinary Medicine (FDA-CVM) and the Australian Pesticides and Veterinary Medicines Authority (APVMA).

The first in-human Clinical Phase I study of intratumoural tigilanol tiglate has been published in The Lancet's EBioMedicine journal

December 2019

An efficacious dose was achieved and a Maximum Tolerated Dose (MTD) was not reached, indicating tigilanol tiglate tolerability in humans. Promising outcomes were attained in patients with a variety of solid tumour types, with a 27% treatment response, including 18% complete response (full tumour destruction). Following these positive results, a Phase I/II trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) is underway, with the first patient successfully dosed.

QBiotics announces first patient dosed in its phase I/II clinical trial of tigilanol tiglate for head and neck cancer

December 2019

First patient successfully dosed in QBiotics' Phase I/II clinical trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC). Tigilanol tiglate is a novel, small molecule that is being tested as a single injection treatment for solid tumours. The Phase I/II clinical trial is a dose escalation study in HNSCC patients designed to determine optimal dosage, safety and tumour response. The QBC46-H03 trial is being run in Australia and India.

Dr Susan Foden joined the Board of QBiotics

October 2019

Dr Susan Foden joined the Board of QBiotics as a non-executive director on 14 October 2019.

International Publication - Tigilanol Tiglate Canine Dose Characterisation Study

11 April 2019

The tigilanol tiglate canine dose characterisation study has been published as an original research article in the leading international journal, Frontiers in Veterinary Science.